Group 1: Company Position and Technology Advantages - The company is a leader in the field of recombinant human collagen, being the only enterprise capable of industrial-scale production of recombinant type III human collagen [5] - It has achieved significant breakthroughs in safety, efficacy, and application scenarios, with over 2 million clinical applications and no observed immunogenicity [5] - The recombinant type III human collagen has a specific 164.88° flexible triple helix structure, with high biological activity recognized by the international protein structure database (PDB) [5] Group 2: Product Launch and Market Strategy - The new product "Wei Yi Mei ColNet," launched in February 2025, is positioned as a high-end product with a specification of 12mg per unit, currently distributed to approximately 100 outlets [6] - The company plans to expand its product system under the "Wei Yi Mei" brand to meet diverse consumer needs and will continue to increase its coverage of medical institutions, which currently includes about 4,000 institutions [9] Group 3: Future Research and Development Focus - The company will deepen the application development of recombinant type III human collagen across various medical fields, including dermatology, gynecology, urology, orthopedics, and cardiovascular [7] - It is also exploring other types of collagen, such as recombinant type XVII and type V human collagen, with some products already in clinical trial stages [7] Group 4: Functional Skincare Products - The sales revenue of functional skincare products is expected to grow rapidly in 2024, driven by the performance of proprietary brands like "Zhongyuan®" and "ProtYouth®" [10] - The sales strategy for 2025 includes building proprietary brands around innovative material advantages and developing raw materials tailored to major customer needs [10]
锦波生物(832982) - 投资者关系活动记录表